anticoagulants frederick villamena, phd associate professor of pharmacology college of medicine the...
TRANSCRIPT
![Page 1: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/1.jpg)
Anticoagulants
Frederick Villamena, PhD
Associate Professor of Pharmacology
College of Medicine
The Ohio State University
![Page 2: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/2.jpg)
Block Objective
Describe• the mechanisms of action• indications• and major side effects of drugs affecting blood coagulation.
![Page 3: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/3.jpg)
Learning Objectives
Understand
• the mechanism of normal clotting.
Name
• the conditions for the use of anticoagulants and antithrombotics.
Classify and nam
e
• commonly used anticoagulants and antithrombotics.
Identify
• the properties, mechanisms of action, pharmacokinetics, side effects, and contraindications of various anticoagulants and antithrombotics.
![Page 4: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/4.jpg)
References
Lilly, L. Pathophysiology of Heart Disease, 5th ed. 2010. Chapter 17, pp. 422-423, 427-431
Harvey, R.A. and Champe, P. C. Pharmacology, 2nd ed. Lippincott Illustrated Reviews.
![Page 5: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/5.jpg)
Mechanism of Normal Clotting
endothelium
platelets (thrombocytes)
collagen fibers
ADP
Thromboxane A2
(TXA2)
GP IIb/IIIa receptors activation
fibrinogenCa2+
thrombin
ADP, thrombinTXA2 synthesis
XII XIIa
XI XIa
IX IXa
X Xa
Ca2+
Ca2+
Ca2+
VIIVIIa
XCa2+
fibrinogen fibrinCa2+
prothrombin (II) thrombin (IIa)Ca2+
fibrin
Intrinsic Pathway (platelets)
Extrinsic Pathway (tissue damage)
![Page 6: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/6.jpg)
Thrombus
Clot adherent to vessel wall or heart chamber wall (as opposed to embolus which is a clot that floats in the blood). Therefore, thrombus may become an embolus.
![Page 7: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/7.jpg)
Indications
A. Thromboembolic disease1. Deep vein thrombosis (DVT), thrombophlebitis
2. Pulmonary embolism
B. Prevention of thrombosis in high risk patients1. Post op
2. Bedridden patients
C. Heart disease1. Arrhythmias (atrial fibrillation and flutter)
2. Mechanical prosthetic heart valves
3. After myocardial infarction of anterior wall
![Page 8: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/8.jpg)
Anticoagulants
Unfractionated Heparin (UFH)
Low molecular weight heparins (LMWH)
Parenteral direct thrombin inhibitors
Oral Anticoagulants (warfarin, Factor Xa and thrombin inhibitors)
![Page 9: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/9.jpg)
Unfractionated Heparin: Properties
Mixture of high and low molecular weights glycosaminoglygans (3-40 kD; ave. m.w. = 15 kD)
Extracted from porcine intestinal mucosa. Highly negative-charged due to sulfate and carboxylate
groups Applied mostly as venous thrombosis prophylaxis in
hospitalized patients Also for prevention of pulmonary embolism, mural
thrombosis after myocardial infarction or atrial arrhythmias, and those with unstable angina and MI.
![Page 10: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/10.jpg)
Heparin: Mechanism of Action
X XaCa2+
XCa2+
fibrinogen fibrinCa2+
prothrombin (II) thrombin (IIa)Ca2+
low heparin dose
high heparin dose
acceleratedbinding to coagulant factors inactivated Factor Xa
or Thrombin (IIa)(also inhibits other proteases)
heparin
antithrombin
Factor Xaor Thrombin (IIa)
heparin does not lyse clot
![Page 11: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/11.jpg)
Heparin: Pharmacokinetics
Rapid-acting anticoagulant Parenterally (deep sub q or intravenously) as a bolus for
immediate anticoagulation followed by continuous infusion. Effect occurs 1-2 hours after sub q injection (or min after IV). Potential benefits may warrant use of the drug in pregnant
women despite potential risks (Cat. C) since it does not penetrate placental barrier.
Binds to plasma protein and taken up by phagocytes hence unpredictability of dose-response.
Excreted in the urine, therefore, dose is decreased for patients with renal impairment.
![Page 12: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/12.jpg)
Heparin: Side Effects
Bleeding complications treated with protamine sulfate, a highly positively-charged peptide.
Antigenic (from porcine source) Thrombosis due to chronic or intermittent use can lead to
reduction of antithrombin III activity Heparin-induced thrombocytopenia (HIT) or immune
mediated heparin-induced thrombocytopenia syndrome (HITS)
HITS is dangerous and associated with bleeding and thrombosis at the same time
Osteoporosis and abnormal liver function from long term use.
![Page 13: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/13.jpg)
Heparin: Contraindication
Bleeding disorder or active bleeding Immune mediated heparin induced thrombocytopenia
(HITS) Alcoholics Recent surgery of the brain, eye or spinal cord
![Page 14: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/14.jpg)
Types of Low Molecular Weight Heparins (LMWH)
• Enoxaparin• Dalteparin• Tinzaparin
Heparin-derived
• FondaparinuxSynthetically derived
![Page 15: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/15.jpg)
Heparin-Derived LMWH
Partially purified low average molecular weight of 5 kD. 1/3 the size of unfractionated heparin Mechanism of action: same as heparin but greater effect on Factor Xa Longer half-lives (3-7 hrs) than heparin (1.5 hrs) Given by injection to patients following surgery of the hip, knee or
abdominal surgery to prevent DVT. In treatment of DVT with or without pulmonary embolism and
management of acute coronary syndrome. Fewer side effects than that of heparin. Do not cross the placenta (Cat. B drug). Less monitoring than heparin therefore is cost effective and useful for
in- and outpatients.
![Page 16: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/16.jpg)
Synthetic LMWH
Example is Fondaparinux. Selectively inhibits Xa Do not bind to protamine FDA approved for deep vein thrombosis leading to pulmonary
embolism. Subq administration to patients with hip fracture/replacement/
surgery. No adverse effects in pregnant women. Lower risk of HIT than with LMWH and heparin. Contraindicated in patients with renal impairement
![Page 17: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/17.jpg)
Direct Thrombin Inhibitors (DTIS)
Bivalirudin Desirudin Lepirudin Argatroban
Dabigatran
(will be discussed under oral
anticoagulants)
BIVALIRUDIN is the most commonly used especially for patients with heparin-induced thrombocytopenia syndrome (HITS)
Major side effect is bleeding.
All are parenterally administered except for Dabigatran which is orally administered.
![Page 18: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/18.jpg)
Oral Anticoagulants
• Warfarin• Dicumarol (rarely used)
Vitamin K antagonist
• DabigatranThrombin inhibitor
• Rivaroxaban• ApixabanXa inhibitors
![Page 19: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/19.jpg)
Warfarin: Mechanism of ActionXII XIIa
XI XIa
IX IXa
X Xa
Ca2+
Ca2+
Ca2+
VIIVIIa
XCa2+
fibrinogen fibrinCa2+
prothrombin (II) thrombin (IIa)Ca2+
Polypeptide precursors to Factors II, VII, IX and X
Active Factors II, VII, IX and X
Vit K (red)O2, CO2
Vit K (ox)
NADP+
NADPH
Warfarin
![Page 20: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/20.jpg)
Warfarin: Indication and Pharmacokinetics
Prevention of thrombosis and thromboembolism. Rapidly absorbed after oral administration. Mostly binds to plasma albumin preventing diffusion into
cerebrospinal fluid, urine, and breast milk. Half-life is ~ 40 hrs. Metabolized by CYP450.
![Page 21: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/21.jpg)
Warfarin: Side Effects
Hemorrhage (principal risk) IV injection of Vit K or whole blood, frozen
plasma/concentrates are used as antidotes for warfarin Purple toe syndrome due to cholesterol emboli Alcohol, aspirin and antiarrhythmic agents can potentiate
anticoagulant effect of warfarin. Antibiotics can reduce the amount of gut flora, therefore, also
potentiating the effect of warfarin. Frequent monitoring of the prothrombin time (INR) needed Phenobarbital and ibuprofen attenuate the effect of warfarin. Teratogenic (FDA pregnancy category X) can cause abortion
or fetal defects (instead heparin or LMWH are used).
![Page 22: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/22.jpg)
Dabigatran
Oral direct thrombin inhibitor Dabigatran etexilate is a prodrug of the active moiety
dabigatran FDA approved for prevention of stroke and systemic
embolism in patients with atrial fibrillation NOT associated with heart valve disease and for treatment of DVT and pulmonary emboli
Prevention of DVT. Pregnancy category C. Only recommended if there is no
alternative. No antidote.
![Page 23: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/23.jpg)
Dabigatran: Mechanism of ActionXII XIIa
XI XIa
IX IXa
X Xa
Ca2+
Ca2+
Ca2+
VIIVIIa
XCa2+
fibrinogen fibrinCa2+
prothrombin (II) thrombin (IIa)Ca2+
![Page 24: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/24.jpg)
Rivaroxaban and Apixaban
Oral Factor Xa inhibitor with rapid onset of action. Prevention of deep vein thrombosis (DVT) in patients
with hip fracture or hip/knee replacement surgery. Used following an acute DVT and pulmonary embolism. As stroke prophylaxis for patients with non-valvular atrial
fibrillation. Both are not indicated for prosthetic heart valves, or for
mitral stenosis, or as an add-on to dual antiplatelet therapy.
No antidote
![Page 25: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/25.jpg)
Rivaroxaban and Apixaban: Mechanism of Action
XII XIIa
XI XIa
IX IXa
X Xa
Ca2+
Ca2+
Ca2+
VIIVIIa
XCa2+
fibrinogen fibrinCa2+
prothrombin (II) thrombin (IIa)Ca2+
![Page 26: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/26.jpg)
Thrombolytics (Fibrinolytics)
Dissolve blood clots Hemorrhage is a major side effect since it cannot distinguish
between fibrin from unwanted thrombus and fibrin from beneficial hemostatic plug.
Tissue plasminogen activator (tPA) is most commonly employed. Used in myocardial infarction with ST segment elevation on ECG. Unstable patients with pulmonary emboli Clotted mechanical prosthetic heart valves. Acute ischemic stroke
Contraindicated in patients with healing wounds or recent major surgery, pregnancy, brain tumor and head trauma/intracranial bleeding.
Antidote is aminocaproic acid.
![Page 27: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/27.jpg)
Thrombolytics: Mechanism of action
plasminogen
plasmin
Tissue plasminogen activator (t-PA)Streptokinase Urokinase
![Page 28: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/28.jpg)
Comparison of Major Anticoagulant Drugs
Drugs
Mechanism of action
Indications
(all used to prevent thrombosis as well)
Route of administration
Adverse effect
Unfractionated Heparin
Thrombin, Xa
Thrombosis (hospitalized
patients)
IV
Subcutaneous
Thrombocytopenia,
bleeding
LMWH
Xa
After orthopedic surgery, DVT and
PE
Subcutaneous
Bleeding, thrombocytopenia, osteoporosis (from
long term use)
Direct Thrombin Inhibitors
Thrombin
Heprain-Induced Thrombocytopenia
(HITS)
IV
Bleeding (contraindicated in renal and hepatic
diseases)
Warfarin
Vitamin K antagonist (II, VII,
IX, X)
Thrombosis (outpatients)
Oral
Bleeding with overdose
Drug interactions
![Page 29: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/29.jpg)
Anticoagulant Drugs Quiz
![Page 30: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/30.jpg)
Thank you for completing this module
• I hope that I was able to teach the subject clearly.• If you have any questions, write to me. [[email protected]]
![Page 31: Anticoagulants Frederick Villamena, PhD Associate Professor of Pharmacology College of Medicine The Ohio State University](https://reader036.vdocument.in/reader036/viewer/2022062314/56649eb35503460f94bba994/html5/thumbnails/31.jpg)
Survey
We would appreciate your feedback on this module. Click on the button below to complete a brief survey. Your responses and comments will be shared with the module’s author, the LSI EdTech team, and LSI curriculum leaders. We will use your feedback to improve future versions of the module.
The survey is both optional and anonymous and should take less than 5 minutes to complete.
Survey